Physician profile
Jack A Dipalma
NPI 1598702805
$902,802.43
in general payments reported to CMS, 2019-2025
16 companies · $106K in 2025
The $106K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149K · 2020: $144K · 2021: $128K · 2022: $127K · 2023: $125K · 2024: $124K · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $355K · Food and Beverage: $610 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $354,774.18 |
| Food and Beverage | $609.79 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $872,713.65 | 2019-2025 | Golytely |
| Puma Biotechnology, INC. | $28,874.40 | 2019-2021 | |
| Abbvie INC. | $214.23 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $188.78 | 2019-2024 | Entyvio, Gattex |
| Covidien Lp | $184.95 | 2020 | |
| Janssen Biotech, INC. | $129.33 | 2022-2024 | Tremfya, Stelara |
| Erbe USA INC | $85.00 | 2022-2024 | |
| Celgene Corporation | $75.84 | 2023-2024 | Zeposia |
| Mahana Therapeutics, INC. | $72.97 | 2022 | |
| Pfizer INC. | $62.99 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $51.50 | 2024 | Dupixent |
| Lilly USA, LLC | $49.47 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.54 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $26.77 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.37 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $17.64 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Dipalma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.